Intervention Review

Heparin for pregnant women with acquired or inherited thrombophilias

  1. Mark C Walker1,*,
  2. Sarah E Ferguson2,
  3. Victoria M Allen3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 22 APR 2003

Assessed as up-to-date: 1 JUL 2002

DOI: 10.1002/14651858.CD003580


How to Cite

Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003580. DOI: 10.1002/14651858.CD003580.

Author Information

  1. 1

    University of Ottawa, Department of Obstetrics and Gynecology, Ottawa, Ontario, Canada

  2. 2

    University of Toronto, Department of Obstetrics and Gynecology, Toronto, Canada

  3. 3

    Dalhousie University, Department of Obstetrics and Gynecology, Halifax, Nova Scotia, Canada

*Mark C Walker, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, K1H 8L6, Canada. mwalker@ohri.ca. mwalker99@hotmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 22 APR 2003

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary

Background

Thrombophilias, which are associated with a predisposition to thrombotic events, have been implicated in adverse obstetrical outcomes such as intrauterine growth restriction, stillbirth, severe early onset pre-eclampsia, and placental abruption. Heparin administration in pregnancy may reduce the risk of these events.

Objectives

The objective of this review was to assess the effects of heparin on pregnancy outcomes for women with a thrombophilia.

Search methods

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (July 2002), MEDLINE, EMBASE, CINAHL, Scidex (via OVID Technologies - July 2002) and reference lists and personal files. We updated the search of the Cochrane Pregnancy and Childbirth Group's Trials Register on 3 August 2012 and added the results to the awaiting classification section.

Selection criteria

Randomized controlled trials comparing heparin with placebo or no treatment, or randomized controlled trials comparing any two treatments. Quasi randomized studies would be included.

Data collection and analysis

Data would be abstracted from identified studies and recorded on a paper form by two reviewers.

Main results

No studies were included.

Authors' conclusions

There are no completed trials to determine the effects of heparin on pregnancy outcomes for women with a thrombophilia.

[Note: The 23 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary

Heparin for pregnant women with acquired or inherited thrombophilias

No evidence from trials on the effects of heparin on pregnancy outcomes for women with a thrombophilia.

Thrombophilias are a group of disorders where the person's blood is prone to thrombosis (clotting). These blood clots can cause life-threatening complications such as DVT (deep vein thrombosis). Thrombophilia can cause a number of serious complications in pregnancy, such as growth restriction, stillbirth and severe pre-eclampsia. Heparin is an anti-clotting drug which thins the blood. It does not seem to have adverse effects on the baby during pregnancy, and few adverse effects on the pregnant woman. However, the review found no trials on the effects of heparin on pregnancy outcomes for women with a thrombophilia.